BIIB up +1.50% percent Today $BIIB High is at 326.39 and the Low 319.00 with current volume of 461,954.
Recent News posted below.
Biogen Idec Inc BIIB other info.
http://investorshangout.com/Biogen-Idec-Inc-BIIB-53494/
BIIB Biogen Idec Inc Recent Headline News
5 Prescription Drugs Selling Like Hot Cakes
Todd Campbell, The Motley Fool - Motley Fool - Sun Nov 09, 9:01AM CST
Considering that 90% of prescription drugs being developed by biotechnology companies will fail during clinical trials, it can be tough to know which biotech stocks to seize upon and which stocks to shun. Instead of focusing on unproven...
MDVN: 110.14 (-2.63), JNJ: 108.49 (+0.29), BIIB: 324.98 (+4.23), PTLA: 27.26 (-0.13), GILD: 108.25 (+1.80), CELG: 107.78 (+1.33)
Medical Device Companies Were Election Day Winners
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 08, 11:00AM CST
Source: Library of Congress The shift in power in Washington may have big implications for medical device companies if legislation is rekindled to ditch the 2.3% medical device tax. That tax, enacted as part of Obamacare to help fund the cost of...
BIIB: 324.98 (+4.23), MDT: 68.44 (+0.34), AMGN: 162.55 (+2.30), SYK: 88.10 (+0.63)
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 324.98 (+4.23), ALNY: 98.61 (+2.77), ISIS: 46.23 (+1.64), OGXI: 2.12 (-0.06), TEVA: 58.12 (+0.42), RGLS: 22.84 (+0.76), GSK: 45.23 (+0.32), SNY: 46.28 (+0.59)
5 Things Biogen Idec Inc's Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 12:50PM CST
In conjunction with its third-quarter earnings, Biogen Idec management held a conference call to discuss the results from the third quarter and its future prospects. Here are the top five things management said on its earnings call. We would...
BIIB: 324.98 (+4.23)
Medivation Q3 Earnings, Revenues Lag Estimates - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Nov 07, 11:08AM CST
Medivation's (MDVN) Xtandi should see strong uptake in the chemo-naive patient population from the fourth quarter.
CYTK: 4.20 (+0.10), MDVN: 110.15 (-2.62), BIIB: 324.98 (+4.23)
Salix Q3 Earnings Marred by Inventory Issues, Cuts View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Nov 07, 10:09AM CST
Salix's (SLXP) Audit Committee has appointed outside counsel to probe the inventory issues.
AGN: 196.74 (+0.74), BIIB: 324.98 (+4.23), AUXL: 32.90 (+0.15), SLXP: 93.30 (+1.83)
Keryx (KERX) in Focus: Stock Adds 11.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:46AM CST
Keryx (KERX) was a big mover last session, with shares rising nearly 12% on the day.
AGEN: 3.00 (-0.02), BIIB: 324.98 (+4.23), AMAG: 34.69 (-0.26), KERX: 16.46 (-0.27)
Study Results, Financial Results, Regulatory Updates, and Upcoming Conference - Research Reports on Medtronic, Zoetis, Biogen, Tenet Health and Aetna
PR Newswire - Fri Nov 07, 7:55AM CST
Today, Analysts Review released its research reports regarding Medtronic, Inc. (NYSE: MDT), Zoetis Inc. (NYSE: ZTS), Biogen Idec Inc. (NASDAQ: BIIB), Tenet Healthcare Corp. (NYSE: THC) and Aetna Inc. (NYSE: AET). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7776-100free.
ZTS: 40.19 (-0.04), BIIB: 324.98 (+4.23), MDT: 68.43 (+0.33), THC: 49.17 (+1.32), AET: 83.38 (+1.09)
Isis Pharmaceuticals earns USD10m milestone payment for advancement of antisense drug ISIS-BIIB3 Rx
M2 - Fri Nov 07, 6:22AM CST
Novel drugs company Isis Pharmaceuticals (NasdaqGS:ISIS) said on Thursday that it expects to receive USD10m milestone payment from Biogen Idec related to the initiation of investigational new drug (IND)-supporting studies of ISIS-BIIB3Rx.
BIIB: 324.98 (+4.23), ISIS: 46.23 (+1.64)
Vertex Pharmaceuticals Seeks Approval for CF Combination - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Nov 06, 5:25PM CST
Priority review and timely approval would allow Vertex Pharmaceuticals (VRTX) to launch this combination in mid-15 in the U.S.
CYTK: 4.20 (+0.10), BIIB: 324.98 (+4.23), VRTX: 116.71 (+0.78), AFFX: 9.46 (+0.03)
Celldex Falls with Pipeline Update Overshadowing Q3 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:57PM CST
Celldex Therapeutics, Inc. (CLDX) amended the protocol for a pivotal study being conducted on glembatumumab vedotin for the treatment of triple negative breast cancer.
BIIB: 324.98 (+4.23), ANIP: 48.84 (+2.84), CLDX: 14.25 (+0.83), AMAG: 34.69 (-0.26)
Alnylam's Q3 Loss Narrower than Expected, Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 11:40AM CST
Alnylam (ALNY) reported third-quarter 2014 loss of 58 cents per share, much wider than the year-ago loss of 48 cents per share.
BIIB: 324.98 (+4.23), ALNY: 98.61 (+2.77), AMAG: 34.69 (-0.26)
Perrigo Misses on Earnings and Sales, Maintains Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 10:08AM CST
Perrigo Companys reported first-quarter fiscal 2015 earnings of $1.40 per share.
AGN: 196.74 (+0.74), BIIB: 324.98 (+4.23), PRGO: 156.48 (+0.71), ABBV: 63.64 (+2.14)
Biogen Idec Foundation to Help NC Science Festival Reach One Million North Carolinians by 2020
PR Newswire - Thu Nov 06, 9:00AM CST
The North Carolina Science Festival (NCSF) announced today that the Biogen Idec Foundation will increase its commitment to NCSF through a new sponsorship that will help sustain the festival for the next three years. The Biogen Idec Foundation will be recognized as "Presenting Sponsor" of the North Carolina Science Festival.
BIIB: 324.98 (+4.23)
Advance Auto Parts Elects Adriana Karaboutis to Its Board of Directors
Business Wire - Thu Nov 06, 7:41AM CST
Advance Auto Parts, Inc. (NYSE: AAP), the largest automotive aftermarket parts provider in North America, serving both professional installer and do-it-yourself customers, today announced that Adriana "Andi" Karaboutis, who currently serves as Executive Vice President, Technology and Business Solutions of Biogen Idec (Biogen), has been elected to Advance's Board of Directors. Ms. Karaboutis' appointment will be effective on February 10, 2015.
BIIB: 324.98 (+4.23), AAP: 143.80 (+1.95)
Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen Idec for Advancement of ISIS-BIIB3 Rx
PR Newswire - Thu Nov 06, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $10 million milestone payment from Biogen Idec related to the initiation of investigational new drug (IND)-supporting studies of ISIS-BIIB3Rx. ISIS-BIIB3Rx is a recently identified development candidate designed to inhibit an undisclosed target to treat a neurodegenerative disease.
BIIB: 324.98 (+4.23), ISIS: 46.23 (+1.64)
Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014 - 38 Companies & 67 Drug Profiles
M2 - Thu Nov 06, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/rdllgl/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Athersys, Inc. - Seattle Genetics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Idera Pharmaceuticals, Inc. - Mesoblast Limited - Jazz Pharmaceuticals plc - Alexion Pharmaceuticals, Inc. - Soligenix, Inc. - NeoStem, Inc. - Pharmacyclics, Inc. - Pluristem Therapeutics Inc. - MediPost Co., Ltd. - Kamada Ltd. - R-Tech Ueno, Ltd. - Omni Bio Pharmaceutical Inc. - Alder Biopharmaceuticals Inc. - MSM Protein Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/rd...ersus_host
BIIB: 324.98 (+4.23), PCYC: 133.37 (-0.12), PSTI: 2.67 (+0.01), NBS: 4.92 (+0.07), ALDR: 16.76 (+0.19), IDRA: 2.42 (-0.01), SGEN: 36.04 (-0.01), JAZZ: 171.97 (+1.17), ALXN: 194.64 (+0.83), KMDA: 3.89 (-0.26), ATHX: 1.50 (-0.03), NVS: 92.52 (+0.76)
Will AVEO Pharmaceuticals (AVEO) Surprise this Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 4:10PM CST
AVEO Pharmaceuticals (AVEO), which is expected to report third-quarter 2014 results on Nov 6, had delivered a positive earnings surprise of 7.89% last quarter.
BIIB: 324.98 (+4.23), AVEO: 0.91 (+0.02), INFI: 13.28 (+0.27), HSP: 56.28 (-0.04)
Jazz Pharmaceuticals Q3 Earnings Rise Y/Y, Lifts Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 1:20PM CST
Jazz Pharmaceuticals' (JAZZ) third-quarter 2014 adjusted earnings of $2.07 per share were above the year-ago adjusted earnings.
BIIB: 324.98 (+4.23), JAZZ: 171.97 (+1.17), AMAG: 34.69 (-0.26)
20 Stocks That Could Beat the Market in November: Priceline, U.S. Steel Lead Way
at The Street - Wed Nov 05, 10:24AM CST
Which stocks have historically done the best in November, typically one of the best months to invest?
BIIB: 324.98 (+4.23), MNST: 106.62 (-1.77), ATI: 31.62 (-1.06), MON: 115.22 (+0.78), GMCR: 155.40 (+2.50), VMC: 65.20 (+0.09), EMR: 65.18 (+0.32), WDC: 97.37 (-0.33), VRSN: 60.51 (+0.71), URBN: 30.66 (-0.52), FSLR: 52.10 (+1.81), DE: 88.38 (-0.28), EXPE: 86.14 (+1.03), FLR: 66.15 (-0.14), FLS: 68.18 (+0.28), X: 36.93 (-0.64), ROK: 112.54 (+0.25), REGN: 383.53 (+5.69), MA: 85.00 (+0.20)
Recent News posted below.
Biogen Idec Inc BIIB other info.
http://investorshangout.com/Biogen-Idec-Inc-BIIB-53494/
BIIB Biogen Idec Inc Recent Headline News
5 Prescription Drugs Selling Like Hot Cakes
Todd Campbell, The Motley Fool - Motley Fool - Sun Nov 09, 9:01AM CST
Considering that 90% of prescription drugs being developed by biotechnology companies will fail during clinical trials, it can be tough to know which biotech stocks to seize upon and which stocks to shun. Instead of focusing on unproven...
MDVN: 110.14 (-2.63), JNJ: 108.49 (+0.29), BIIB: 324.98 (+4.23), PTLA: 27.26 (-0.13), GILD: 108.25 (+1.80), CELG: 107.78 (+1.33)
Medical Device Companies Were Election Day Winners
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 08, 11:00AM CST
Source: Library of Congress The shift in power in Washington may have big implications for medical device companies if legislation is rekindled to ditch the 2.3% medical device tax. That tax, enacted as part of Obamacare to help fund the cost of...
BIIB: 324.98 (+4.23), MDT: 68.44 (+0.34), AMGN: 162.55 (+2.30), SYK: 88.10 (+0.63)
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 324.98 (+4.23), ALNY: 98.61 (+2.77), ISIS: 46.23 (+1.64), OGXI: 2.12 (-0.06), TEVA: 58.12 (+0.42), RGLS: 22.84 (+0.76), GSK: 45.23 (+0.32), SNY: 46.28 (+0.59)
5 Things Biogen Idec Inc's Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 12:50PM CST
In conjunction with its third-quarter earnings, Biogen Idec management held a conference call to discuss the results from the third quarter and its future prospects. Here are the top five things management said on its earnings call. We would...
BIIB: 324.98 (+4.23)
Medivation Q3 Earnings, Revenues Lag Estimates - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Nov 07, 11:08AM CST
Medivation's (MDVN) Xtandi should see strong uptake in the chemo-naive patient population from the fourth quarter.
CYTK: 4.20 (+0.10), MDVN: 110.15 (-2.62), BIIB: 324.98 (+4.23)
Salix Q3 Earnings Marred by Inventory Issues, Cuts View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Nov 07, 10:09AM CST
Salix's (SLXP) Audit Committee has appointed outside counsel to probe the inventory issues.
AGN: 196.74 (+0.74), BIIB: 324.98 (+4.23), AUXL: 32.90 (+0.15), SLXP: 93.30 (+1.83)
Keryx (KERX) in Focus: Stock Adds 11.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:46AM CST
Keryx (KERX) was a big mover last session, with shares rising nearly 12% on the day.
AGEN: 3.00 (-0.02), BIIB: 324.98 (+4.23), AMAG: 34.69 (-0.26), KERX: 16.46 (-0.27)
Study Results, Financial Results, Regulatory Updates, and Upcoming Conference - Research Reports on Medtronic, Zoetis, Biogen, Tenet Health and Aetna
PR Newswire - Fri Nov 07, 7:55AM CST
Today, Analysts Review released its research reports regarding Medtronic, Inc. (NYSE: MDT), Zoetis Inc. (NYSE: ZTS), Biogen Idec Inc. (NASDAQ: BIIB), Tenet Healthcare Corp. (NYSE: THC) and Aetna Inc. (NYSE: AET). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7776-100free.
ZTS: 40.19 (-0.04), BIIB: 324.98 (+4.23), MDT: 68.43 (+0.33), THC: 49.17 (+1.32), AET: 83.38 (+1.09)
Isis Pharmaceuticals earns USD10m milestone payment for advancement of antisense drug ISIS-BIIB3 Rx
M2 - Fri Nov 07, 6:22AM CST
Novel drugs company Isis Pharmaceuticals (NasdaqGS:ISIS) said on Thursday that it expects to receive USD10m milestone payment from Biogen Idec related to the initiation of investigational new drug (IND)-supporting studies of ISIS-BIIB3Rx.
BIIB: 324.98 (+4.23), ISIS: 46.23 (+1.64)
Vertex Pharmaceuticals Seeks Approval for CF Combination - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Nov 06, 5:25PM CST
Priority review and timely approval would allow Vertex Pharmaceuticals (VRTX) to launch this combination in mid-15 in the U.S.
CYTK: 4.20 (+0.10), BIIB: 324.98 (+4.23), VRTX: 116.71 (+0.78), AFFX: 9.46 (+0.03)
Celldex Falls with Pipeline Update Overshadowing Q3 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:57PM CST
Celldex Therapeutics, Inc. (CLDX) amended the protocol for a pivotal study being conducted on glembatumumab vedotin for the treatment of triple negative breast cancer.
BIIB: 324.98 (+4.23), ANIP: 48.84 (+2.84), CLDX: 14.25 (+0.83), AMAG: 34.69 (-0.26)
Alnylam's Q3 Loss Narrower than Expected, Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 11:40AM CST
Alnylam (ALNY) reported third-quarter 2014 loss of 58 cents per share, much wider than the year-ago loss of 48 cents per share.
BIIB: 324.98 (+4.23), ALNY: 98.61 (+2.77), AMAG: 34.69 (-0.26)
Perrigo Misses on Earnings and Sales, Maintains Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 10:08AM CST
Perrigo Companys reported first-quarter fiscal 2015 earnings of $1.40 per share.
AGN: 196.74 (+0.74), BIIB: 324.98 (+4.23), PRGO: 156.48 (+0.71), ABBV: 63.64 (+2.14)
Biogen Idec Foundation to Help NC Science Festival Reach One Million North Carolinians by 2020
PR Newswire - Thu Nov 06, 9:00AM CST
The North Carolina Science Festival (NCSF) announced today that the Biogen Idec Foundation will increase its commitment to NCSF through a new sponsorship that will help sustain the festival for the next three years. The Biogen Idec Foundation will be recognized as "Presenting Sponsor" of the North Carolina Science Festival.
BIIB: 324.98 (+4.23)
Advance Auto Parts Elects Adriana Karaboutis to Its Board of Directors
Business Wire - Thu Nov 06, 7:41AM CST
Advance Auto Parts, Inc. (NYSE: AAP), the largest automotive aftermarket parts provider in North America, serving both professional installer and do-it-yourself customers, today announced that Adriana "Andi" Karaboutis, who currently serves as Executive Vice President, Technology and Business Solutions of Biogen Idec (Biogen), has been elected to Advance's Board of Directors. Ms. Karaboutis' appointment will be effective on February 10, 2015.
BIIB: 324.98 (+4.23), AAP: 143.80 (+1.95)
Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen Idec for Advancement of ISIS-BIIB3 Rx
PR Newswire - Thu Nov 06, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $10 million milestone payment from Biogen Idec related to the initiation of investigational new drug (IND)-supporting studies of ISIS-BIIB3Rx. ISIS-BIIB3Rx is a recently identified development candidate designed to inhibit an undisclosed target to treat a neurodegenerative disease.
BIIB: 324.98 (+4.23), ISIS: 46.23 (+1.64)
Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014 - 38 Companies & 67 Drug Profiles
M2 - Thu Nov 06, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/rdllgl/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Athersys, Inc. - Seattle Genetics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Idera Pharmaceuticals, Inc. - Mesoblast Limited - Jazz Pharmaceuticals plc - Alexion Pharmaceuticals, Inc. - Soligenix, Inc. - NeoStem, Inc. - Pharmacyclics, Inc. - Pluristem Therapeutics Inc. - MediPost Co., Ltd. - Kamada Ltd. - R-Tech Ueno, Ltd. - Omni Bio Pharmaceutical Inc. - Alder Biopharmaceuticals Inc. - MSM Protein Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/rd...ersus_host
BIIB: 324.98 (+4.23), PCYC: 133.37 (-0.12), PSTI: 2.67 (+0.01), NBS: 4.92 (+0.07), ALDR: 16.76 (+0.19), IDRA: 2.42 (-0.01), SGEN: 36.04 (-0.01), JAZZ: 171.97 (+1.17), ALXN: 194.64 (+0.83), KMDA: 3.89 (-0.26), ATHX: 1.50 (-0.03), NVS: 92.52 (+0.76)
Will AVEO Pharmaceuticals (AVEO) Surprise this Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 4:10PM CST
AVEO Pharmaceuticals (AVEO), which is expected to report third-quarter 2014 results on Nov 6, had delivered a positive earnings surprise of 7.89% last quarter.
BIIB: 324.98 (+4.23), AVEO: 0.91 (+0.02), INFI: 13.28 (+0.27), HSP: 56.28 (-0.04)
Jazz Pharmaceuticals Q3 Earnings Rise Y/Y, Lifts Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 1:20PM CST
Jazz Pharmaceuticals' (JAZZ) third-quarter 2014 adjusted earnings of $2.07 per share were above the year-ago adjusted earnings.
BIIB: 324.98 (+4.23), JAZZ: 171.97 (+1.17), AMAG: 34.69 (-0.26)
20 Stocks That Could Beat the Market in November: Priceline, U.S. Steel Lead Way
at The Street - Wed Nov 05, 10:24AM CST
Which stocks have historically done the best in November, typically one of the best months to invest?
BIIB: 324.98 (+4.23), MNST: 106.62 (-1.77), ATI: 31.62 (-1.06), MON: 115.22 (+0.78), GMCR: 155.40 (+2.50), VMC: 65.20 (+0.09), EMR: 65.18 (+0.32), WDC: 97.37 (-0.33), VRSN: 60.51 (+0.71), URBN: 30.66 (-0.52), FSLR: 52.10 (+1.81), DE: 88.38 (-0.28), EXPE: 86.14 (+1.03), FLR: 66.15 (-0.14), FLS: 68.18 (+0.28), X: 36.93 (-0.64), ROK: 112.54 (+0.25), REGN: 383.53 (+5.69), MA: 85.00 (+0.20)
